

## APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

## APPENDIX A

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333.

## APPENDIX A

**MINIMAL RISK LEVEL (MRL) WORKSHEET**

Chemical Name: Cyanide and compounds  
CAS Numbers:  
Date: March 2006  
Profile Status: Post Public, Final  
Route:  Inhalation  Oral  
Duration:  Acute  Intermediate  Chronic  
Graph Key: 21  
Species: Rat

Minimal Risk Level: 0.05  mg/kg/day  ppm

Reference: NTP. 1993. NTP technical report on toxicity studies of sodium cyanide administered in drinking water to F344/N rats and B6C3F1 mice. Toxicity Report No. 37. National Toxicology Program, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. NIH Publication 94-3386.

Experimental design: For the main study, 10 male and 10 female rats were given drinking water containing sodium cyanide at concentrations of 0, 3, 10, 30, 100, or 300 ppm for 13 weeks. A supplemental set of 10 males/group was assigned for interim examinations of hematology, clinical chemistry, and urinalysis examinations. The intakes of cyanide during that period averaged 0, 0.2, 0.5, 1.4 (males) or 1.7 (females), 4.5 (males) or 4.9 (females), or 12.5 mg/kg/day, respectively. Rats in the base study were observed twice daily. Body weights were recorded at the start of the study, weekly thereafter, and at necropsy. Clinical observation were recorded weekly. Water consumption by cage was measured weekly. Blood from the base study rats was collected on days 86 (males) and 93 (females), and from the supplemental study rats on days 5, 25, 45, and 92 for hematology and clinical chemistry. Urinalysis samples were collected from the supplemental rats on days 8, 22, 43, and 88. Complete necropsies were performed for all rats in the base study. The heart, kidneys, liver, lung, testes, and thymus were weighed. Complete histopathologic examinations of all gross lesions, tissue masses, and more than 35 tissues were performed on all animals in the 0 and 12.5 mg/kg/day dose groups. In the other exposed groups, all gross lesions, the liver (males only), spleen, and urinary bladder were examined for histopathology. Functional reproductive parameters were evaluated in main study rats in the 0, 30, 100, and 300 ppm groups. Vaginal cytology and sperm motility evaluations were performed for 12 days prior to sacrifice. Numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined from vaginal swabs to ascertain estrous cycle stage and the percentage of cycle spent in the various stages; the vagina in these rats was examined for histopathology. At necropsy, reproductive tissue weights were recorded for males, and data were recorded for epididymal sperm motility, density, and spermatogenesis.

Effects noted in study and corresponding doses: Exposure to cyanide had no significant effect on survival, body weight gain, the incidence of clinical signs, nonreproductive organ weights (absolute or relative to body weight), hematology, or clinical chemistry parameters. Water consumption was about 10% lower in the two highest exposure groups, and concomitantly, urine volume was decreased and urine specific density was increased; the authors suggested that these findings indicated a palatability problem at the two highest doses. Urinary thiocyanate levels were increased in most exposed groups, indicative of biotransformation of ingested cyanide. No treatment-related gross or histopathologic lesions were observed in rats, including potential target tissues such as the corpus callosum of the brain and the follicular epithelium of the thyroid gland (susceptible to the anti-thyroid effects of the metabolite thiocyanate).

## APPENDIX A

Some cyanide-related effects were observed in the study of reproductive parameters. Statistically significant decreases compared to controls were observed in the absolute weights of the left epididymis (-7%), left cauda epididymis (-13%), and left testis (-7.6%) of rats treated at 12.5 mg/kg-day. In addition, 13.6% reductions compared to controls were observed in spermatid heads per testis and spermatid counts per mL suspension in rats treated at 12.5 mg/kg/day. The authors considered these to be evidence of a mild adverse effect of cyanide on the male reproductive system. The statistically significant reductions (7.4–8.6% lower than controls) in left cauda epididymis weights observed at 1.4 and 4.5 mg/kg/day were not considered biologically significant in the absence of any other significant effect. The small (<4%), statistically significant, but not dose-related, reductions observed in spermatozoa motility in the 1.4, 4.5, and 12.5 mg/kg/day groups were within the range of normal values and were not considered biologically significant by the authors. For females, significantly ( $p=0.03$ , Wilk's Criterion) more time was spent in proestrus and diestrus stages and less time in estrus and metestrus stages in the 4.9 and 12.5 mg/kg/day dose groups than in controls, but a dose-relationship was not observed. For this reason, the authors did not consider these results unequivocal proof that cyanide adversely affects the female reproductive system.

Dose and end point used for MRL derivation: 4.5 mg/kg/day, based on the NOAEL for no reproductive effects in male rats.

[X] NOAEL [ ] LOAEL

Uncertainty Factors used in MRL derivation: 100

- [ ] 00 for use of a LOAEL
- [X] 10 for extrapolation from animals to humans
- [X] 10 for human variability

MRL = 4.5 mg/kg/day/100 = 0.05 mg/kg/day

Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes.

If so, explain: The doses based on water consumption as reported by NTP (1993) were 0, 0.3, 0.9, 1.0, 2.7, 3.2, 8.5, 9.2, 23.5, and 23.6 mg NaCN/kg/day. These doses were converted from sodium cyanide to cyanide by multiplying each dose by 0.53 ( $CN^-/NaCN$ ); resulting in dose levels of 0, 0.2, 0.5, 1.4 (males), 1.7 (females), 4.5 (males), 4.9 (females), or 12.5 mg/kg/day cyanide.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: NA

Was a conversion used from intermittent to continuous exposure? NA

Other additional studies or pertinent information that lend support to this MRL: No studies are available for the intermediate-duration oral toxicity of humans exposed to known quantities of cyanide, but there are a number of studies in animals exposed to sodium or potassium cyanide (as discussed in Section 3.2.2). However, not all studies are suitable for establishing dose-response relationships. Several studies (Gerhart 1986, 1987; Jackson 1988; Soto-Blanco et al. 2002a) in rats and pigs report neurological, thyroid, and gastrointestinal effects following gavage administration of cyanide; however, their usefulness for dose-response assessment is limited because the bolus dosing may overwhelm the detoxification process and is not characteristic of typical general population exposures to cyanide in drinking water. Similarly, although a toxicity study in dogs receiving sodium cyanide reported effects in the male reproductive system, adrenal gland, and kidney, the lower levels of the detoxifying enzyme rhodanese in this species both increases the sensitivity to cyanide and prevents the production of the metabolite

## APPENDIX A

thiosulfate to levels that would be toxic to the thyroid as seen in humans and other animals (Kamalu 1993). Additionally, studies involving exposure to cyanide via a cassava diet (Tewe and Maner 1981a, 1981b) were not considered as the basis of an MRL because there is evidence suggesting that other toxic compounds, such as scopoletin, may contribute to the observed toxic effects (Kamalu 1993).

In rat and mice exposed to sodium cyanide in drinking water for 13 weeks (NTP 1993), reproductive effects in males were the only adverse effects observed. Effects on male reproduction included reductions in epididymal weights (-13%), testicular weights (-8%), and spermatid counts (-13.6%) in F344 rats exposed to 12.5 mg CN<sup>-</sup>/kg/day, and 10–18% reductions in epididymal/caudal epididymal weights in B6C3F1 mice exposed to 24.3 mg CN<sup>-</sup>/kg/day. In rabbits exposed to sodium cyanide in the diet at doses of 15 mg CN<sup>-</sup>/kg/day for 4 weeks or 20 mg CN<sup>-</sup>/kg/day for 40 weeks, hepatic toxicity (fatty degeneration and necrosis of the liver, increased serum levels of succinate dehydrogenase, alanine aminotransferase, and alkaline phosphatase) and renal toxicity (tubular necrosis) were observed (Okolie and Iroanya 2003; Okolie and Osagie 1999). Neurotoxicity (myelin degeneration in the spinal cord) was observed in rats exposed at 30 mg CN<sup>-</sup>/kg/day as potassium cyanide in food for 11.5 months (Philbrick et al. 1979). Effects on male reproduction were severe in dogs (germ cell sloughing and degeneration, reduced spermatogenesis cycle) (Kamalu 1993) and also observed in rats and mice in studies in which no other systemic effects were observed. Hepatic, renal, and body weight effects were reported in Wistar rats that received doses of 3.6 mg CN<sup>-</sup>/kg/day as potassium cyanide in drinking water for 15 days (Sousa et al. 2002a). However, the reliability of these findings is questionable because of the lack of incidence data for the histopathological lesions and because no body weight effects were noted in other rat studies with exposures for longer durations and at higher doses. On the basis of these considerations, reproductive toxicity in males is selected as the critical effect of cyanide toxicity. The NTP (1993) bioassay in rats is selected as the principal study because it provided the lowest LOAEL and a NOAEL for the critical effect and examined the full range of tissues with extensive interim hematological, clinical chemistry, and urinalyses.

Agency Contacts (Chemical Managers): Jessilynn Taylor, Nickolette Roney, Carolyn Harper

APPENDIX A

This page is intentionally blank.

## APPENDIX B. USER'S GUIDE

### Chapter 1

#### Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

### Chapter 2

#### Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

#### Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not

## APPENDIX B

meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

## **Chapter 3**

### **Health Effects**

#### **Tables and Figures for Levels of Significant Exposure (LSE)**

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.



## APPENDIX B

**LEGEND****See Sample LSE Table 3-1 (page B-6)**

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system,

## APPENDIX B

which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

- (9) **LOAEL.** A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) **Reference.** The complete reference citation is given in Chapter 9 of the profile.
- (11) **CEL.** A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) **Footnotes.** Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

**LEGEND**

**See Sample Figure 3-1 (page B-7)**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) **Exposure Period.** The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) **Health Effect.** These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) **Levels of Exposure.** Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m<sup>3</sup> or ppm and oral exposure is reported in mg/kg/day.
- (16) **NOAEL.** In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) **CEL.** Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

## APPENDIX B

- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels ( $q_1^*$ ).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

**SAMPLE**

1 →

**Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation**

Key to figure <sup>a</sup>	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
					Less serious (ppm)	Serious (ppm)	
<b>INTERMEDIATE EXPOSURE</b>							
	5	6	7	8	9		10
3 →	Systemic	↓	↓	↓	↓	↓	↓
4 →	18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 <sup>b</sup>	10 (hyperplasia)	Nitschke et al. 1981
<b>CHRONIC EXPOSURE</b>							
	Cancer					11	
					↓		
	38	Rat	18 mo 5 d/wk 7 hr/d			20	(CEL, multiple organs) Wong et al. 1982
	39	Rat	89–104 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, nasal tumors) NTP 1982
	40	Mouse	79–103 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, hemangiosarcomas) NTP 1982


12 →

<sup>a</sup> The number corresponds to entries in Figure 3-1.

<sup>b</sup> Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  $5 \times 10^{-3}$  ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

SAMPLE

**Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation**



APPENDIX B

This page is intentionally blank.

**APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS**

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD	benchmark dose
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CL	ceiling limit value
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor
DOT	Department of Transportation

## APPENDIX C

DOT/UN/ NA/IMCO	Department of Transportation/United Nations/ North America/International Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F <sub>1</sub>	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
FT <sub>3</sub> I	free triiodothyronine index
FT <sub>4</sub> I	free thyroxine index
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K <sub>d</sub>	adsorption ratio
kg	kilogram
kkg	metric ton
K <sub>oc</sub>	organic carbon partition coefficient
K <sub>ow</sub>	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC <sub>50</sub>	lethal concentration, 50% kill
LCGU	local cerebral glucose utilization
LC <sub>Lo</sub>	lethal concentration, low
LD <sub>50</sub>	lethal dose, 50% kill
LD <sub>Lo</sub>	lethal dose, low
LDH	lactic dehydrogenase
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT <sub>50</sub>	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid



## APPENDIX C

MAL	maximum allowable level
mCi	millicurie
MCL	maximum contaminant level
MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration

## APPENDIX C

OSW	Office of Solid Waste, EPA
OTS	Office of Toxic Substances
OW	Office of Water
OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SIC	standard industrial classification
SIM	selected ion monitoring
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
T <sub>3</sub>	triiodothyronine
T <sub>4</sub>	thyroxine
TD <sub>50</sub>	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TSH	thyroid stimulating hormone
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey

## APPENDIX C

VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization

>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q <sub>1</sub> *	cancer slope factor
-	negative
+	positive
(+)	weakly positive result
(-)	weakly negative result

APPENDIX C

This page is intentionally blank.

## APPENDIX D. INDEX

absorbed dose .....	14, 104
adrenal gland .....	21, 57, 82, 91, 94, 99
adrenals.....	82, 94, 99
adsorption .....	173
aerobic .....	90, 91, 93, 109, 155, 173, 175, 176, 177
alanine aminotransferase .....	21, 55
ambient air .....	213, 218
anaerobic.....	90, 92, 106, 155, 173, 176, 177
anemia .....	7, 42, 53
aspartate aminotransferase (see AST).....	52
asphyxia.....	15, 36, 52, 97
AST (see aspartate aminotransferase).....	52, 54
atropine.....	115
bioaccumulation .....	168
bioavailability .....	76, 126, 183, 196
biodegradation .....	13, 150, 151, 155, 167, 172, 173, 174, 175, 176, 177, 195, 196, 218
biomarker.....	14, 103, 104, 106, 107, 124, 125, 126, 191, 201, 206, 217
body weight effects.....	22, 39, 58, 66
breast milk .....	85, 126, 186, 191
cancer.....	6, 7, 60, 65, 101, 185, 221
carcinogen.....	228
carcinogenic.....	18, 25, 98
carcinogenicity .....	7, 16, 122, 221
carcinoma .....	73, 74, 122
cardiovascular.....	20, 36, 52, 70, 96, 102, 114, 120, 121, 125
cardiovascular effects .....	36, 52, 70, 96, 121
cassava.....	2, 4, 7, 8, 9, 13, 15, 16, 17, 18, 21, 23, 27, 43, 52, 55, 56, 57, 58, 59, 61, 63, 64, 65, 84, 102, 111, 112, 120, 121, 123, 124, 125, 128, 166, 183, 184, 186, 188, 189, 193, 198
clearance .....	85, 111
cytochrome c .....	14, 90, 91, 92, 95, 105, 106, 108, 110, 111, 114, 125
death .....	6, 9, 14, 16, 19, 25, 27, 28, 40, 42, 43, 62, 66, 70, 72, 75, 77, 91, 93, 94, 95, 103, 104, 105, 106, 113, 115, 116, 117, 120, 124, 129, 185
deoxyribonucleic acid (see DNA).....	72, 74
dermal effects .....	38, 39, 57, 71
DNA (see deoxyribonucleic acid).....	16, 72, 73, 74, 75, 94, 104, 122
dopamine .....	61, 94, 96, 116, 129
endocrine .....	38, 66, 99
endocrine effects.....	38, 56
estrogen receptor.....	100
estrogenic.....	100
fetus .....	8, 101, 103
gastrointestinal effects .....	20, 21, 37, 53, 70, 102
general population .....	4, 5, 9, 13, 21, 43, 63, 64, 65, 103, 112, 113, 155, 156, 157, 186, 187, 192, 195, 197
genotoxic .....	16, 25, 72, 73, 122
genotoxicity .....	73, 75, 122
goiter.....	15, 56, 98, 106, 111, 218
groundwater.....	13, 155, 164, 165, 167, 168, 179, 180, 193
growth retardation.....	64, 123
half-life .....	3, 75, 80, 103, 105, 108, 167, 169, 174, 176, 195
hematological effects.....	37, 53
hematopoietic .....	53
hepatic effects.....	37, 54, 55, 107

## APPENDIX D

hydrolysis .....	60, 117, 131, 169, 170, 172, 174, 175, 177, 182, 183, 187, 196
hydroxocobalamin .....	14, 80, 84, 91, 109, 115
hydroxyl radical .....	155, 169, 172
immunological .....	25, 39, 59, 71, 123
immunological effects .....	39, 59, 71, 123
iodide .....	97, 174
$K_{ow}$ .....	135, 136, 137, 138, 139, 167, 168, 194
$LD_{50}$ .....	15, 42, 43, 66, 99, 108, 110, 111, 115, 116, 120
metabolic effects .....	19, 59
milk .....	8, 16, 102, 128, 156
musculoskeletal effects .....	37, 54
neurobehavioral .....	17, 100, 128
neurochemical .....	106
neuropathy .....	17, 58, 62, 90, 106
neurotransmitter .....	16, 91
ocular effects .....	39, 58, 71
Parkinsonism .....	60, 120
partition coefficients .....	194
pharmacodynamic .....	85
pharmacokinetic .....	82, 85, 86, 87, 101, 108, 127
photolysis .....	155, 169, 172, 173, 175
placenta .....	8, 103, 126
rate constant .....	169, 172, 176
renal effects .....	38, 55, 56, 70
rhodanese .....	14, 15, 19, 21, 28, 41, 43, 64, 65, 80, 82, 97, 99, 108, 110, 111, 113, 125, 126, 127, 174
serum glutamic oxaloacetic transaminase (see SGOT) .....	54
serum glutamic pyruvic transaminase (see SGPT) .....	54
SGOT (see serum glutamic oxaloacetic transaminase) .....	54
SGPT (see serum glutamic pyruvic transaminase) .....	54
solubility .....	88, 166, 194
spermatozoa .....	23
T3 .....	38, 56, 57
T4 .....	38, 56, 57
thiocyanate .....	3, 4, 5, 6, 7, 8, 9, 15, 16, 38, 56, 58, 62, 63, 75, 77, 79, 80, 82, 84, 85, 89, 90, 97, 102, 104, 108, 109, 110, 111, 113, 117, 123, 124, 125, 126, 127, 129, 134, 139, 141, 142, 149, 150, 151, 155, 156, 157, 159, 164, 165, 166, 168, 174, 175, 177, 179, 181, 182, 184, 187, 188, 189, 191, 192, 193, 194, 196, 197, 198, 201, 202, 203, 205, 206, 210, 214, 215, 216, 217, 218, 224, 225
thyroid .....	3, 7, 8, 15, 20, 21, 27, 38, 56, 57, 90, 97, 98, 102, 111, 124, 126, 221
thyroid stimulating hormone (see TSH) .....	15, 20, 38, 56
thyroxine .....	56, 57, 97
toxicokinetic .....	25, 80, 85, 126, 127
tremors .....	17, 20, 41, 72, 93, 108
triiodothyronine .....	56
TSH (see thyroid stimulating hormone) .....	38
vapor phase .....	139
volatility .....	166
volatilization .....	155, 158, 166, 167, 168, 172, 176, 177, 195, 196, 206
weanling .....	65, 123